SYS6090, a holding subsidiary of CSPC Pharmaceutical Innovation (300765.SZ), launches phase IB/II clinical trial

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Bio”), has recently launched a Phase Ib/II clinical trial (SYS6090-007) to evaluate the safety, tolerability and efficacy of SYS6090 injection combination therapy in hepatocellular carcinoma participants.

The SYS6090-007 clinical trial launched this time is an open, multi-center phase Ib/II clinical trial. The purpose is to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in hepatocellular carcinoma participants. Based on the results of this study, the company will continue to advance phase III clinical studies of SYS6090 injection combined treatment in hepatocellular carcinoma participants to further verify the efficacy and safety of SYS6090 injection. Currently, the recruitment and screening of participants for the SYS6090-007 study is being actively promoted.